背景:中性粒细胞与淋巴细胞比率(NLR),淋巴细胞与单核细胞比率(LMR),和托盘淋巴细胞比率(PLR)目前被验证为廉价和可获得的生物标志物在不同类型的实体瘤,包括头颈癌(HNC)。
目的:为了评估NLR的可能目的和生物标志物价值,PLR,和MLR记录HNC的治疗前(放疗/化疗)。
方法:来自Craiova县急诊医院肿瘤科门诊(2002年1月至2022年12月)的肿瘤记录中纳入的190例HNC患者,39例符合纳入标准(鳞状细胞癌和计算治疗前(化疗/放疗)NLR值的可能性,PLR,还有MLR.总生存期(OS)值与NLR相关,PLR,还有MLR.
结果:NLR的中值,PLR,MLR为6.15(1.24-69),200.79(61.3-1775.0),和0.53(0.12-5.5),分别。在研究中,NLR的平均值,PLR,和MLR分别为2.88、142.97和0.36,已获得。研究组的中位OS为11个月(1-120)。尽管存在Pearson的负相关,变量之间的关系很弱,值R=0.07,p=0.67,R=0.02,p=0.31和R=0.07,p=0.62与NLR相关,PLR,还有MLR,分别,与OS相关。NLR的中值,PLR,对于治疗前NLR值<2的HNC病例和NLR值≥6的HNC病例(分别为23.5、232.78和0.79),计算MLR(分别为1.53、90.32和0.18).NLR<2和NLR≥6的病例的中位OS分别为17.4个月和13个月,分别。
结论:数据的比较分析突出了NLR值低的情况对OS的益处。不仅在HNSCC中作为预后标志物的临界NLR值(在2和6之间)的作用,而且在预后评分中包括PLR和MLR也必须在将来定义。选择更统一的纳入标准的前瞻性研究可以证明治疗前NLR的价值,PLR,和MLR通过加强或降低HNSCC的非手术治疗来进行治疗分层。
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and pallets-to-lymphocyte ratio (PLR) are currently validated as cheap and accessible biomarkers in different types of solid tumors, including head and neck cancers (HNC).
OBJECTIVE: To evaluate the possible purposes and biomarker value of NLR, PLR, and MLR recorded pre-treatment (radiotherapy/chemotherapy) in HNC.
METHODS: From 190 patients with HNC included in the oncology records in the oncology outpatient clinic of the Craiova County Emergency Hospital (from January 2002 to December 2022), 39 cases met the inclusion criteria (squamous cell carcinoma and the possibility to calculate the pre-treatment (chemotherapy/radiotherapy) value of NLR, PLR, and MLR. Overall survival (OS) values were correlated with NLR, PLR, and MLR.
RESULTS: The median values for NLR, PLR, and MLR were 6.15 (1.24-69), 200.79 (61.3-1775.0), and 0.53 (0.12-5.5), respectively. In the study, the mean values for NLR, PLR, and MLR of 2.88, 142.97, and 0.36, respectively, were obtained. The median OS in the study group was 11 months (1-120). Although a negative Pearson\'s correlation was present, the relationship between the variables was only weak, with values of R = 0.07, p = 0.67, R = 0.02, p = 0.31, and R = 0.07, p = 0.62 being related to NLR, PLR, and MLR, respectively, in correlation with OS. The median values of NLR, PLR, and MLR were calculated (1.53, 90.32, and 0.18, respectively) for the HNC cases with pre-treatment values of NLR < 2 and for the HNC cases with NLR values ≥ 6 (23.5, 232.78, and 0.79, respectively). The median OS for cases with NLR < 2 and NLR ≥ 6 were 17.4 and 13 months, respectively.
CONCLUSIONS: The comparative analysis of the data highlights a benefit to OS for cases low values of NLR. The role of not only borderline NLR values (between 2 and 6) as a prognostic marker in HNSCC but also the inclusion of PLR and MLR in a prognostic score must also be defined in the future. Prospective studies with more uniformly selected inclusion criteria could demonstrate the value of pre-treatment NLR, PLR, and MLR for treatment stratification through the intensification or de-escalation of non-surgical curative treatment in HNSCC.